Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Videos>This Video


Advance drug discovery by improving dose-response curve set-up

Tecan Group Ltd.

Richard Marcellus, Molecular Biologist, Ontario Institute for Cancer Research Save time and reduce waste while improving data quality for small molecule dose-response curves Titration of small molecules in DMSO is a ubiquitous part of the drug discovery workflow. Traditional methods require serial dilution which can be wasteful in terms of tips, intermediate plates and compounds. This process is also time consuming, and reproducibility from researcher to researcher can be a challenge. Traditionally, laboratories have had to accept the potential for carry-over and accumulated pipetting errors, as well as the high labor costs associated with this task. In addition, many laboratories are not performing scientifically optimal titrations, due to equipment or time restrictions. For example, in vitro drug-drug interaction experiments are often desired, but are too complicated to perform routinely. Low- and medium-throughput laboratories, such as therapeutic or lead optimization departments, cannot always justify the purchase of large automation equipment. Not only can the cost of these systems be prohibitive, they can also impose undesirable limits on assay set-up, and often require specialist knowledge to maintain and program. These laboratories need an affordable solution that meets their demands for flexibility, speed and reliability. Join our webinar as we examine the potential for change in dose-response curve set-up for small molecules in DMSO, leading to time savings and dose and plate layout flexibility for drug discovery biologists. Key Learning Objectives • Explore methods to save time and reduce labor costs when setting up dose-response curves • Save precious compounds and eliminate waste of consumables and reagents • Quickly set up drug-drug interaction experiments, along with other complex plate layouts • Improve data quality in dose-response curves and decrease the number of bioassay wells required Richard C. Marcellus, Ph.D. Biochemist - Ontario Institute for Cancer Research, Toronto, Canada Richard has spent over a decade working in cancer drug discovery and has broad experience ranging from target identification, to assay development and HTS, SPR-based protein-drug interaction analysis, and drug target validation. He currently works in the Medicinal Chemistry Group at the OICR, a translational research institute. Richard runs in vitro assays in support of SAR programs, and has embarked upon a targeted screening program in patient-derived primary cancer cells. In this study drug sensitivity is being combined with RNAi and deep sequencing to identify promising anti-cancer targets.

Request more information
Company product page

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos